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gn the general topic area of cardiac arrhythmias, 497
bstracts were submitted for consideration and 160 were
ccepted for presentation at the 2006 ACC meeting. In
ddition, late-breaking clinical trials were presented eval-
ating ablation of atrial fibrillation (AF), prevention of
ostoperative atrial fibrillation, and treatment of neurally
ediated syncope.
REATMENT OF AF
he Ablation for Paroxysmal Atrial Fibrillation (APAF)
rial was a randomized, controlled study of circumferential
ulmonary vein ablation versus antiarrhythmic drug therapy
or paroxysmal atrial fibrillation (1). The trial enrolled 198
atients (age 57  10 years, 66% male) with paroxysmal
trial fibrillation, who were then randomized to catheter
blation or antiarrhythmic therapy using flecainide, sotalol,
r amiodarone. As of March 2006, nine-month follow-up
as completed for 150 patients. The primary end point of
he study was freedom from AF at 12 months, which was
chieved in 87% of patients who underwent catheter abla-
ion compared with 29% of patients treated with antiar-
hythmic drugs. Repeat ablation was required in five pa-
ients because of recurrent AF or atrial tachycardia. In
ddition, evidence of left atrial reverse remodeling was
resent based on a decrease in left atrial dimensions in
atients who had catheter ablation. A secondary analysis
ndicated that amiodarone and flecainide were superior to
otalol at the dosages used in this trial (freedom from atrial
brillation 50% vs. 38% vs. 6%, respectively).
A retrospective, case-control study of pulmonary vein
solation (PVI), direct current cardioversion, and atrioven-
ricular node ablation for atrial fibrillation was reported by
akkireddy et al. (2). Cases were matched for baseline
linical characteristics, and the mean age of patients in each
tudy arm was 70 years. The study involved a total of 138
atients in the PVI group, 139 in the cardioversion group,
nd 133 in the atrioventricular node ablation group; proce-
ures were performed between 1996 and 2004. Long-term
ortality rates were significantly lower in the PVI group
ompared with cardioversion and atrioventricular node ab-
ation (1.4% vs. 15% vs. 31%). Also, there were fewer
trokes and transient ischemic attacks in the PVI group (4%
s. 18% vs. 5%).
Results were reported of a phase III randomized,
lacebo-controlled, multicenter trial of a novel antiarrhyth-
ic drug, RSD1235, in patients with AF or atrial flutter.
ratt et al. (3) randomized 276 patients to RSD1235 ore
From the Cornell University Medical Center-New York Presbyterian Hospital,
ivision of Cardiology, New York, New York.lacebo stratified by duration of arrhythmia. Fifty-two
ercent of patients treated with the active drug had a
onversion to sinus rhythm versus 4% in the placebo group.
f note, there was no evidence of torsades de pointes in the
reatment group. There was one death in a patient with
ritical aortic stenosis who received RSD1235.
PIDEMIOLOGY AND PREVENTION OF AF
he influence of race on susceptibility to AF was examined
n a meta-analysis by Novaro et al. (4). Seven randomized
linical trials in acute myocardial infarction and acute
oronary syndromes were included, resulting in a pooled
opulation of 95,787 patients (2.9% African American,
7.1% Caucasian). Although African-American patients
ad higher prevalences of hypertension, diabetes, tobacco,
nd prior myocardial infarction, the incidence of atrial
brillation was lower in African-American versus Caucasian
atients (4.3% vs. 7.6%).
To examine the role of race with regard to ischemic
troke in AF, Shen et al. (5) conducted a review of the
aiser Permanente database of hospitalized patients in
outhern California. After identifying all patients hospital-
zed for nonrheumatic AF, African-American patients were
ound to have a higher risk of stroke regardless of whether
hey were taking warfarin during follow-up. The hazard
atio for ischemic stroke in AF for African Americans was
.6 compared with Caucasians, after adjusting for the
nown stroke risk factors of age, gender, warfarin use,
ypertension, diabetes, and heart failure (Table 1). The
ame group found a different race profile for the risk of
emorrhagic stroke in patients with AF treated with war-
arin (6). There was a progressive increase in hemorrhagic
isk from Caucasian, African-American, Hispanic, and
sian subgroups (adjusted hazard ratios 1, 1.97, 2.24, and
.43, respectively). These studies implicate the role of
enetic factors in the development of AF and stroke.
Gender differences in ischemic stroke risk were studied
y Konety et al. (7) through an analysis of the Atrial
ibrillation Follow-Up Investigation of Rhythm Man-
gement (AFFIRM) trial. Of the 4,060 patients enrolled
n this trial, 39% were women. Prescription rates of
arfarin were similar for men and women, but absolute
troke rates were higher for women (5.0%) compared with
en (3.1%). The relative risk of stroke remained elevated in
omen despite adjustment for multiple known stroke risk
actors, international normalized ratio, and randomization
roup. These findings highlight the importance of consid-
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June 6, 2006:D28–32 ACC 2006 Annual Session HighlightsBrar et al. (8) studied the association of diabetes, insulin, and
revalence of AF and flutter in a large heart failure population.
hey used a managed care database of 28,009 patients with
eart failure, of whom 48% had diabetes; of the diabetic
atients, 38% were insulin users. Insulin users had less atrial
brillation, with an odds ratio of 0.81 compared with nondi-
betic patients, but diabetic non-insulin users did not differ
ignificantly from nondiabetic patients with regard to the
revalence of AF. They concluded that insulin use may be
rotective against AF in patients with heart failure.
The role of left atrial dilatation in the pathogenesis of AF
as addressed through an echocardiographic study by
achtell et al. (9). They analyzed echocardiograms for 939
ypertensive patients with left ventricular hypertrophy ran-
omized in the Losartan Intervention For Endpoint reduc-
ion in hypertension (LIFE) study, a randomized study of
tenolol or losartan for antihypertensive treatment, with
atients followed up for a mean of 4.8 years. In 58 patients,
F developed during follow-up, and predictors of new-
nset AF were baseline left atrial diameter (hazard ratio
.93 per cm higher) and reduction of left atrial diameter
Table 1. Hazard Ratios for Ischemic Stroke in
On W













AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-Up
Investigation of Rhythm Management
trial
APAF-3  Ablation for Paroxysmal Atrial
Fibrillation
ARMYDA-3  Atorvastatin for Reduction of
Myocardial Dysrhythmias After Cardiac
Surgery trial
FDA  Food and Drug Administration
HOPE  Heart Outcomes Prevention Evaluation
trial
ICD  implantable cardioverter-defibrillator
LIFE  Losartan Intervention For Endpoint
reduction in hypertension trial
MADIT II  Multicenter Automatic Defibrillator
Implantation Trial II
PVI  pulmonary vein isolationReprinted with permission (5).
CI  confidence interval.ith treatment (hazard ratio 0.19 per cm lower). They
oncluded that monitoring left atrial dimension may con-
ribute to the prevention of AF during antihypertensive
reatment by prompting further intervention to achieve a
eduction in left atrial diameter.
Salehian et al. (10) studied the effects of ramipril and
itamin E on the incidence of AF in the Heart Outcomes
revention Evaluation (HOPE) study. The study enrolled
,334 patients in sinus rhythm at baseline, all of whom were
t least 55 years of age with cardiovascular disease or
iabetes plus one risk factor for cardiovascular disease. The
atients were randomized in a 2  2 factorial design to
amipril, vitamin E, or the combination and followed up for
n average of 4.5 years. There was no significant difference
n the development of AF in the ramipril and placebo
roups (2.0% vs. 2.25%). A different conclusion was reached
n a study by Jibrini et al. (11), who performed a meta-analysis
f seven randomized, controlled trials of angiotensin-
onverting enzyme inhibitors or angiotensin receptor blockers
n different cardiovascular subsets. Treatment with these agents
educed the relative risk of AF in patients with hypertension by
3%, after myocardial infarction by 11%, after cardioversion by
1%, and in patients with heart failure by 32%.
A randomized trial of atorvastatin showed a reduction of
ostoperative AF after cardiac surgery in the Atorvastatin
or Reduction of Myocardial Dysrhythmias After Cardiac
urgery (ARMYDA-3) trial (12). As presented by Dr. Di
ciascio, 200 patients undergoing elective cardiac surgery
ere randomized to receive atorvastatin (40 mg daily) or
lacebo starting seven days before surgery. Occurrence of
n-hospital AF was significantly lower in the statin group
35%) versus the placebo group (57%), and treatment benefit
as independent of possible confounding factors, with a 60%
isk reduction evident by multivariate analysis. Peak postoper-
tive levels of C-reactive protein were significantly lower in
atients without AF, irrespective of the study assignment. The
nvestigators concluded that atorvastatin significantly reduces
ostoperative AF and that the anti-inflammatory effects of
tatins may contribute to this clinical effect.
al Fibrillation
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MPLANTABLE CARDIOVERTER-DEFIBRILLATORS
how et al. (13) studied the predictive value of QRS
uration and microvolt T-wave alternans testing in patients
ith ischemic cardiomyopathy. In a prospective database of
68 patients with ischemic heart disease and ejection frac-
ions 35%, univariate predictors of long-term mortality
ncluded a nonnegative T-wave alternans test and a QRS
uration 120 ms. In a multivariate model, T-wave
lternans but not QRS duration was predictive of all-
ause and arrhythmic mortality, and there was no inter-
ction between T-wave alternans and QRS duration. The
djusted hazard ratio of a nonnegative T-wave alternans
as 2.24 for all-cause long-term mortality and 2.29 for
rrhythmic mortality.
Aryana et al. (14) studied the circadian, daily, and
easonal distribution of ventricular tachyarrhythmias in
atients with implantable cardioverter-defibrillators (ICDs).
n this retrospective review of 154 ICD recipients, sponta-
eous episodes of ventricular tachycardia and fibrillation
ere more common in the winter (51% of episodes), and
here was a significant correlation between average daily
emperature and ventricular tachycardia and fibrillation.
entricular arrhythmias were more common on Fridays
16.5% of episodes), and the circadian pattern showed a
imodal distribution with more episodes in the morning and
vening.
Recalls and safety alerts for implantable defibrillators
ere addressed in two studies. Hauser et al. (15) conducted
six-year prospective multicenter study of defibrillator pulse
enerators that failed or required replacement because of
anufacturer recalls. They found that average implant times
f failed or recalled generators were shorter for devices with
ate-responsive pacing and cardiac resynchronization. They
oncluded that devices with advanced pacing capabilities are
ore likely to show poor performance related to premature
attery depletion, electronic or housing failure, and manu-
acturers’ recalls. Kendig et al. (16) retrospectively reviewed
he long-term mortality of 1,644 patients who had defibril-
ators implanted between 1996 and 2004 in their institution.
orty-three percent of recipients had a device subject to a
.S. Food and Drug Administration (FDA) recall or safety
lert. The long-term mortality of patients with devices
ot subject to a recall or alert was 30%, and there was no
xcess long-term mortality identified in patients with
evices subject to recalls or alerts (31% with FDA class I
ecalls, 24% with FDA class II recalls, 38% with safety
lerts) (Fig. 1).
Three abstracts identified a poor prognosis in patients with
enal dysfunction who received an ICD. Goldenberg et al. (17)
etrospectively analyzed the outcomes associated with renal
ysfunction in patients enrolled in Multicenter Automatic
efibrillator Implantation Trial II (MADIT-II). For each
0-unit reduction in estimated glomerular filtration rate, they
ound that the risk of mortality increased by 16%. No ICD penefit was documented in patients with the most severe
enal dysfunction (35 ml/1.73 m2). Cuculich et al. (18)
eported that chronic kidney disease was a strong indepen-
ent predictor of mortality in patients with ischemic or
onischemic cardiomyopathy who had ICD implantation
or primary prevention of sudden death (hazard ratio 10.5).
obesh et al. (19) showed 63% mortality at two years in
emodialysis patients who received ICDs after syncope or
ardiac arrest.
ARDIAC RESYNCHRONIZATION
everal studies assessed the predictive value of noninvasive
esting for response to cardiac resynchronization. In a study
f 40 patients with coronary disease who met indications for
ardiac resynchronization, Bleeker et al. (20) reported that a
ransmural posterolateral scar detected by contrast-enhanced
agnetic resonance imaging predicted failure to have a re-
ponse to biventricular pacing. In the absence of posterolateral
car and the presence of severe dyssynchrony, the response
ate to resynchronization was 95%, as assessed by an
mprovement of 1 New York Heart Association func-
ional class and an improvement of 25% in 6-min walk
istance. In patients with severe dyssynchrony but the
resence of a posterolateral scar, the response rate remained
ow at 18%.
Further evidence supporting the importance of scar loca-
ion in cardiac resynchronization was reported by Jansen
t al. (21). In this study of 49 patients, contrast-enhanced
agnetic resonance imaging identified posterolateral scar in
3, other scar in 10, and no scar in 16. Resynchronization
esulted in less acute hemodynamic benefit (as assessed by
hange in acute left ventricular dP/dt) in patients with
osterolateral scar compared with other scar or no scar. The
atients with posterolateral scar also had less remodeling as
ssessed by change in left ventricular systolic volume.
Similarly, Sauer et al. (22) reported that left ventricular
ead positioning over infarcted myocardium results in less
mprovement in ejection fraction in patients with ischemic
ardiomyopathy. Of 108 patients, 21 had left ventricular
eads positioned over an infarcted segment, as identified by
ither nuclear imaging or echocardiography before the
igure 1. Prevalence and impact on patient mortality of Food and Drug
dministration (FDA) recalls and safety alerts relating to implantable
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June 6, 2006:D28–32 ACC 2006 Annual Session Highlightshe group with leads positioned over infarcted compared
ith noninfarcted territory (1.4% vs. 3.9%).
The benefits of site-specific pacing to prevent adverse
emodeling were studied by Tse et al. (23) in a randomized
tudy of 29 patients with high-grade atrioventricular block
nd no structural heart disease. Patients were randomized to
mplantation of the ventricular lead at the right ventricular
eptum or the apex. In the group with septal implantation,
here was no change in ejection fraction over 24 months of
ollow-up, but apical implantation resulted in a reduction
n ejection fraction from 54% to 47%. Septal pacing was
ssociated with more synchronous left ventricular con-
raction.
EURALLY MEDIATED SYNCOPE
n a randomized trial of 223 patients, van Dijk et al. (24)
ested the effects of physical counterpressure maneuvers to
revent recurrent neurally mediated syncope. The median
early syncope burden was significantly lower among pa-
ients trained in counterpressure maneuvers (median 0.0)
ompared with patients who had conventional treatment
median 0.6). During a mean follow-up of 14 months, 51%
f patients with conventional treatment versus 32% of patients
rained in these maneuvers experienced recurrent syncope.
ONCLUSIONS
n summary, the 2006 American College of Cardiology
nnual Scientific Session highlighted one of the first
andomized clinical trials showing the superiority of cathe-
er ablation over antiarrhythmic drug therapy in selected
atients with paroxysmal AF. Race was identified as a risk
actor for AF and stroke, emphasizing the need for further
tudy of genetic influences on these conditions. Strategies to
revent AF through antihypertensive management were
valuated, and a randomized trial for prophylaxis of post-
perative AF with statin therapy was presented. Efforts to
efine risk stratification for sudden death were reported, as
ere studies concerning the outcomes of patients who
eceived implantable defibrillators. Prediction of response to
esynchronization was a topic addressed by several interest-
ng studies, particularly in patients with ischemic cardiomy-
pathy.
eprint requests and correspondence: Dr. Steven M. Markow-
tz, Cornell University Medical Center-New York Presbyterian
ospital, Division of Cardiology, Starr-4, 525 East 68th Street,
ew York, New York 10021. E-mail: smarkow@med.cornell.edu.
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